Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yooo, don’t forget insider ownership of 34%. Buy up what you can!
What is up with that?
Speaking of HGEN and CDMO, volume is nearly identical for both today. Too coincidental.
Well, we should get a lift from
HGEN when they publicize the submission of the EUA application. Considering HGEN is at the top of the XBI and many biotechs fluctuate with the index, CDMO could get a double bonus. Let’s hope we can exceed today’s highs.
News but no premarket buying? Are we that boring now?
Is it only coincidence that CDMO and HGEN price match plus the bid/ask are the same?
Avid Biosciences it is!
Sadly, the die hard followers of CYDY are now grasping for answers (and making excuses). Conspiracy theories, etc. FDA is corrupt. But you listen to 15 minutes of Nader talking and any outsider realizes how much of a snake oil salesman he is.
Feeling very confident about HGEN going into the end of the month.
I suspect Humanigen is not striking a deal outside the US until EUA is approved. If negotiations are in the works, the U.S. price should set a precedent. I can be patient until then, however, without a solid dollar amount in a PR we are at the mercy of shorts.
Hmmmm, interesting. I did not catch that before on the CDMO board.
Quote
I also suspect their CEO (Helen) and CDMO's ex-CEO (Steven) to be more then just business partners :) which possibly yielded business Avids way (speculation).
It’s not a sexy stock, but glad to see it stabilized. As they say, accumulation now for a big move later.
Tennisboy speaking again? I can’t hear it.
I have always wondered why Humanigen has not extended an offering to the EU, India, Brazil, etc. and taken a ‘first come, first serve’ distribution attitude. It makes me wonder if the company and the FDA have a “handshake “ type agreement for the initial batch of 100k doses to treat Covid.
Good call Don!
Decent report for Halo. Should give Avid a boost.
Need proof. Otherwise your claims are worthless.
LOL! No private messaging for me. Thanks for the clarification.
GS is preparing for their upgrade from $21.
Such a shame how much blatant manipulation occurs in the market and the SEC does nothing.
6 whole shares. Try harder next time.
I guess we should be prepared for some hit articles to surface. Seems to be the next step in the playbook.
According to Fidelity, there are 0 (ZERO!) shares to short. If a short squeeze were to occur, right now is about the best time for it.
On the bright side, even the shorts barely pushed this below $17.
Agreed
Pin it!
I try to monitor short covering daily. Today was about 130k shares. Very unscientific considering the many methods hedge funds use to ‘hide their shorting. Regardless, today was higher than the previous three days. Maybe because it’s Friday? Maybe to safely avoid a Monday squeeze? Not sure. But volume covered versus the total short volume is tiny. We need big news to break the trend.
Both companies are tight lipped about future plans. Avid more so than Humanigen. But HGEN future is somewhat out of their control.
If Lenz is approved, both companies should do well. Still a few weeks out (conservatively) before we know EUA but it should get approval in the long run for various conditions outside of Covid.
Long term looks great for both companies.
Part of why I bought into HGEN is they are partnered with Avid Bioservices (CDMO) and I became intrigued with Lenz.
Will Lonza be the European supplier of Lenz?
Good news, though, that HGEN is getting set for deployment.
It has been deduced that EUA application would be submitted around 30 days after P3 results were released. Next week would be the timeframe for that to happen, correct? And I still believe the turnaround for approval will be unprecedented. Therefore, I wouldn’t want to be short going into this weekend. Volume will likely surge.
I’ll take the puppet show over the clown show any day! But let’s try to keep this about HGEN, please.
For the sake of catching the shorts off guard, I do hope the same. But realistically, we’ll have the application submitted in the next few days and then a quick approval. Based on all the discussion, it sounds as though the application is a necessary formality. Either way, I can wait it out. I am very confident in approval and moving forward.
I anticipate the turnaround between EUA application and EUA approval to be unprecedentedly quick. Considering all the correspondence and big names attached, along with the heightened need, approval will not take a month.
That is why EUA application is exciting. Shorts will want to cover sooner rather than later.
Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer
4/21/21, 6:00 AM
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer, effective immediately, reporting to Dr. Cameron Durrant, CEO of Humanigen.
Dr. Kilcoyne brings to Humanigen strong leadership experience from multinational pharmaceutical and biotechnology companies and a strong clinical background in both Internal Medicine and Public Health Medicine. His most recent leadership role was in AstraZeneca, where he served as Vice President of Oncology Global Medical Affairs, Head of Evidence Generation and External Alliances, and previously as Vice President and Head of US Medical Affairs and Health Economics and Outcomes Research. Dr. Kilcoyne oversaw the development and delivery of the fully integrated global evidence strategy across the company’s complete oncology portfolio, including managing development of real-world evidence, epidemiology, biostatistics and data sciences, health economics and outcomes research, payer evidence, medical affairs sponsored research, and investigator research. He also led Global Oncology External Alliances, building strong scientific partnerships to advance patient care.
“Humanigen is delighted to welcome Dr. Kilcoyne,” said Dr. Durrant. “His experience and knowledge in multiple areas, including COVID-19, CAR-T and other oncology clinical development areas, medical affairs, regulatory affairs, evidence generation, health economics, and partnering gives him a unique insight that can be leveraged towards Humanigen’s COVID-19, acute GvHD, CAR-T and other oncology programs with lenzilumab and ifabotuzumab. In addition, Adrian’s leadership in the external alliances arena will be instrumental in helping guide the progress of Humanigen’s pipeline and potential commercialization.”
During his tenure at AstraZeneca, Dr. Kilcoyne oversaw multiple launches of innovative therapies in oncology, including acalabrutinib, a Bruton’s tyrosine kinase inhibitor, in the US (marketed as CALQUENCE®) which has also been investigated in two Phase 2 studies in COVID-19 patients. Previously, Dr. Kilcoyne held several leadership positions at Celgene Corporation, a subsidiary of Bristol Myers Squibb, including Executive Medical Director, Global Lymphoma Program Lead, Clinical Research and Development overseeing the development of lenalidomide in Diffuse Large B-Cell Lymphoma (DLBCL). He was also the US lymphoma CAR-T lead supporting the clinical development and launch preparation of lisocabtagene maraleucel (or liso-cel, marketed as Breyanzi®) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy. Prior to this, Dr Kilcoyne held Medical Affairs and Clinical Development leadership roles in Sanofi Pasteur MSD, Roche and Eli Lilly.
Dr. Kilcoyne’s responsibilities as Humanigen Chief Medical Officer include the clinical development and regulatory strategy for lenzilumab across its varied potential therapeutic indications including CAR-T, acute GvHD, CMML and COVID-19. Additionally, Dr. Kilcoyne will be responsible for the clinical development and regulatory strategy for ifabotuzumab in solid tumors. Dr. Kilcoyne will also be responsible for medical affairs, real-world evidence generation, health economics and outcomes and participate in external alliance evaluation.
“I am excited to join the Humanigen team at this time and look forward to the opportunity to contribute to the company’s strategic long-term growth. I am honored to have the opportunity to deliver on the promise that Humanigen’s innovative portfolio offers to patients with significant unmet medical need,” said Dr. Kilcoyne.
Dr. Kilcoyne graduated from Trinity College, Dublin and holds a MSc in Public Health from the London School of Hygiene and Tropical Medicine, along with a MSc in Business Administration from the Warwick Business School. He is the co-author of Pharmaceutical Medicine, a textbook published by Oxford Specialist Handbooks in 2013, edition 2 now being finalized.
Prove it. Prove KITE dropped HGEN. You can’t! Yet you speculate based on playground antics.
Quote: if they don't pick up partnerships for the P2 CAR-T there are going to be huge financial implications for the company to go it alone.
Unless they have that partner in place and dropping KITE was a necessary step in inking the deal. Besides, there are plenty of courters looking at HGEN. It is only a matter of time now.
I’m guessing we get EUA application PR on Thursday of this week.
EUA approval will be expedited for May 4th.
Enjoy!
Thanks 4ourretirement!
Westjtter, how is Monday the estimated date of the preferred buyout?
OT sort of: sounds like AF is attacking HGEN but they are fighting back.
Remember the days of AF and Peregrine? He should have been in prison years ago for the slander he does on the BPs behalf.
For those of us invested in both HGEN and CDMO that would not be bad news at all! HGEN would flourish without a doubt. CDMO might still retain the contract. If all documentation is in place and waiting for the green light, using CDMO may be the quickest route to market. Or, at least it gains the attention of BPs who are looking for US manufacturing capacity.
It’s cool. Just go with it.